Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz
Bibliographic Data
| ID | 11490301 |
|---|---|
| Authors | Sung Wook Kim, Sungwook Kim (0000-0002-1254-5038, University of Warwick), Jolene Skordis-Worrall (0000-0002-8633-0208, London School of Hygiene & Tropical Medicine) |
| Year | 2017 |
| Volume | 32 |
| Issue | 4 |
| Pages | czw165 |
| Publication date | 2017-01-04 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Health Policy and Planning (JOURNAL) |
| Journal identifiers | ISSN: 0268-1080 • E-ISSN: 1460-2237 |
| Publisher | Oxford University Press (PUBLISHER • GB) |
| DOI | 10.1093/heapol/czw165 |
| PMID | 28052986 |
| OpenAlex | W2569262104 |
| Language | EN |
| Citations received | 3 |
| References cited | 39 |
PURPOSE: : A number of strategies have aimed to assist countries in procuring antiretroviral therapy (ARV) at lower prices. In 2009, as the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) commenced a voluntary pooled procurement scheme, however, the impact of the scheme on ARV prices remains uncertain. This study aims to estimate the effect of VPP on drug prices using Efavirenz as a case study. METHODS: This analysis uses WHO Global price report mechanism (GPRM) data from 2004 to 2013. Due to the highly skewed distribution of drug Prices, a generalized linear model (GLM) was used to conduct a difference-in-difference estimation of drug price changes over time. RESULTS: These analyses found that voluntary pooled procurement reduced both the ex-works price of generic Efavirenz and the incoterms price by 16.2 and 19.1%, respectively ( P < 0.001) in both cases). The year dummies were also statistically significant from 2006 to 2013 ( P < 0.001), indicating a strong decreasing trend in the price of Efavirenz over that period. CONCLUSION: Voluntary pooled procurement significantly reduced the price of 600 mg generic Efavirenz between 2009 and 2013. Voluntary pooled procurement therefore offers a potentially effective strategy for the reduction in HIV drug prices and the improvement of technical efficiency in HIV programming. Further work is required to establish if these findings hold also for other drugs.
Actuarial science · Antiretroviral therapy · Business · Drug prices · Economics · Efavirenz · Human immunodeficiency virus (HIV) · Nevirapine · Procurement · Public economics · Turnover · Viral load · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · Marketing · Medicine · Pharmaceutical Economics and Policy · Virology
Generalized Linear Models
Health Care Systems in Low- and Middle-Income Countries
Outsourcing at Will
A Practitioner’s Guide to Cluster-Robust Inference
Mostly Harmless Econometrics
Intervening in global markets to improve access to HIV/Aids treatment
A win-win solution
The make or buy debate
Enhancing medicine price transparency through price information mechanisms
Estimating the Effect of Training Programs on Earnings
Robust Standard Errors in Small Samples
Inference with “Difference in Differences” with a Small Number of Policy Changes
Tracking humanitarian funding for reproductive health
Exploring the influence of the Global Fund and the Gavi Alliance on health systems in conflict-affected countries
Factors influencing global antiretroviral procurement prices
The Economic Costs of Conflict
| Citations per year | 1 |
|---|---|
| Citation span | 2023 - 2025 (3) |
| Highly cited | No |